Develops implantable medical devices for sacropelvic disorders. Offers the iFuse Implant System for sacroiliac joint dysfunction. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 22% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 4.1× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 58% of them.
Analysts' average target sits 25% above today's price.
The stock trades 36% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 22% a year on average.
Sales run at $200.9M a year. A small number, but proof the product has real buyers.
There is $147.8M in the vault; even if every debt were paid off, $146.7M would remain.
A loss of $18.9M against $200.9M in annual sales.
Over the last 12 months, executives reported 112 sells against just 23 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, SIBN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SIBN is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (58/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.